Supernus Pharmaceuticals (SUPN) Competitors

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, community ranking, analyst recommendations, valuation, institutional ownership and dividends.

Does the MarketBeat Community prefer JAZZ or SUPN?

Jazz Pharmaceuticals received 652 more outperform votes than Supernus Pharmaceuticals when rated by MarketBeat users. Likewise, 80.77% of users gave Jazz Pharmaceuticals an outperform vote while only 72.92% of users gave Supernus Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Jazz Pharmaceuticals	Outperform Votes 1126 80.77%	Underperform Votes 268 19.23%
Supernus Pharmaceuticals	Outperform Votes 474 72.92%	Underperform Votes 176 27.08%

Is JAZZ or SUPN more profitable?

Jazz Pharmaceuticals has a net margin of 11.60% compared to Supernus Pharmaceuticals' net margin of 9.16%. Jazz Pharmaceuticals' return on equity of 29.30% beat Supernus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	11.60%	29.30%	9.72%
Supernus Pharmaceuticals	9.16%	7.79%	5.67%

Which has more risk & volatility, JAZZ or SUPN?

Jazz Pharmaceuticals has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500.

Which has stronger earnings & valuation, JAZZ or SUPN?

Jazz Pharmaceuticals has higher revenue and earnings than Supernus Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$3.83B	2.14	$414.83M	$7.10	19.16
Supernus Pharmaceuticals	$607.52M	3.00	$1.32M	$1.07	30.89

Do insiders & institutionals believe in JAZZ or SUPN?

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 4.2% of Jazz Pharmaceuticals shares are owned by insiders. Comparatively, 9.3% of Supernus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Do analysts prefer JAZZ or SUPN?

Jazz Pharmaceuticals currently has a consensus price target of $180.33, indicating a potential upside of 32.59%. Supernus Pharmaceuticals has a consensus price target of $36.00, indicating a potential upside of 8.93%. Given Jazz Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Jazz Pharmaceuticals is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.93
Supernus Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

Does the media favor JAZZ or SUPN?

In the previous week, Supernus Pharmaceuticals had 13 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 21 mentions for Supernus Pharmaceuticals and 8 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 1.07 beat Supernus Pharmaceuticals' score of -0.28 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Supernus Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	6 Very Negative mention(s)	Neutral

Summary

Jazz Pharmaceuticals beats Supernus Pharmaceuticals on 13 of the 18 factors compared between the two stocks.